[{"orgOrder":0,"company":"Menarini","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"$12.1 million","upfrontCash":"Undisclosed","newsHeadline":"Lupin Inks Pact to Acquire 5 Drug Brands from Menarini for Rs 101 Crore","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Sodium Picosulfate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Menarini","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Menarini \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."}]

Find Clinical Drug Pipeline Developments & Deals for disodium [4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex 2024
                          Not Confirmed
                          Pharmaconex 2024
                          Not Confirmed

                          Details : The company has signed an agreement to acquire five legacy brands are Piclin, Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor) cateri...

                          Product Name : Piclin

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 22, 2023

                          Lead Product(s) : Sodium Picosulfate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Lupin Ltd

                          Deal Size : $12.1 million

                          Deal Type : Acquisition

                          blank